Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2020

27.11.2019 | Original Article

Sequential Versus Combined Heart–Liver Transplantation in the USA

verfasst von: Yoshikazu Yamaguchi, Candice Burrier, Catherine Roth, Dmitry Tumin, Eliza W. Beal, Kenneth Washburn, Don Hayes Jr., Joseph D. Tobias

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Combined heart–liver transplantation (CHLT) has resulted in acceptable survival rates compared to orthotopic liver transplantation (OLT) alone and orthotopic heart transplantation alone. Using the US transplant registry, we compared outcomes following sequential and combined HLT.

Methods

We conducted a retrospective cohort study. De-identified data were obtained from the United Network Organ Sharing Registry. The primary outcome was patient survival from the date of OLT. Secondary outcomes included liver allograft survival and heart allograft survival.

Results

The study cohort included 301 CHLT recipients and six sequential heart–liver transplantation (SHLT) recipients. Patient survival after CHLT was 88% at 1 year, 84% at 3 years, and 82% at 5 years compared to 83%, 67%, and 50% in the SHLT group (p = 0.010). Liver allograft survival at 1, 3, and 5 years was 88%,83% and 82%, respectively, in the CHLT group compared to 83% and 67%, and 50%, respectively, in the SHLT group (p = 0.009). After OLT, heart allograft survival at 1, 3, and 5 years was 86%, 79%, and 74% in the CHLT group, respectively, compared to 83%, 67%, and 50% in the SHLT group (p = 0.037).

Conclusions

Despite the limited size of the SHLT cohort, we found that CHLT was superior to SHLT in survival rate and graft survival. The better outcomes noted in CHLT may relate to immunoprotection provided by liver transplantation from the same donor.
Literatur
1.
Zurück zum Zitat Cannon RM, Hughes MG, Jones CM, Eng M, Marvin MR. A review of the United States experience with combined heart–liver transplantation. Transpl Int. 2012;25:1223–1228.CrossRef Cannon RM, Hughes MG, Jones CM, Eng M, Marvin MR. A review of the United States experience with combined heart–liver transplantation. Transpl Int. 2012;25:1223–1228.CrossRef
2.
Zurück zum Zitat Bradley EA, Pinyoluksana KO, Moore-Clingenpeel M, Miao Y, Daniels C. Isolated heart transplant and combined heart–liver transplant in adult congenital heart disease patients: insights from the united network of organ sharing. Int J Cardiol. 2017;228:790–795.CrossRef Bradley EA, Pinyoluksana KO, Moore-Clingenpeel M, Miao Y, Daniels C. Isolated heart transplant and combined heart–liver transplant in adult congenital heart disease patients: insights from the united network of organ sharing. Int J Cardiol. 2017;228:790–795.CrossRef
3.
Zurück zum Zitat Barbara DW, Rehfeldt KH, Heimbach JK, Rosen CB, Daly RC, Findlay JY. The perioperative management of patients undergoing combined heart–liver transplantation. Transplantation. 2015;99:139–144.CrossRef Barbara DW, Rehfeldt KH, Heimbach JK, Rosen CB, Daly RC, Findlay JY. The perioperative management of patients undergoing combined heart–liver transplantation. Transplantation. 2015;99:139–144.CrossRef
4.
Zurück zum Zitat Nelson LM, Penninga L, Sander K, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transpl. 2013;27:203–209.CrossRef Nelson LM, Penninga L, Sander K, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transpl. 2013;27:203–209.CrossRef
5.
Zurück zum Zitat Figuera D, Ardaiz J, Martín-Júdez V, et al. Combined transplantation of heart and liver from two different donors in a patient with familial type IIa hypercholesterolemia. J Heart Transpl. 1986;5:327–329. Figuera D, Ardaiz J, Martín-Júdez V, et al. Combined transplantation of heart and liver from two different donors in a patient with familial type IIa hypercholesterolemia. J Heart Transpl. 1986;5:327–329.
6.
Zurück zum Zitat Beal EW, Mumtaz K, Hayes D Jr, Whitson BA, Black SM. Combined heart–liver transplantation: indications, outcomes and current experience. Transpl Rev. 2016;30:261–268.CrossRef Beal EW, Mumtaz K, Hayes D Jr, Whitson BA, Black SM. Combined heart–liver transplantation: indications, outcomes and current experience. Transpl Rev. 2016;30:261–268.CrossRef
7.
Zurück zum Zitat Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL. Comparison of renal allograft outcomes in combined liver–kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS database. Transplantation. 2006;82:1298–1303.CrossRef Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL. Comparison of renal allograft outcomes in combined liver–kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS database. Transplantation. 2006;82:1298–1303.CrossRef
8.
Zurück zum Zitat Pinderski LJ, Kirklin JK, McGiffin D, et al. Multi-organ transplantation: is there a protective effect against acute and chronic rejection? J Heart Lung Transpl. 2005;24:1828–1833.CrossRef Pinderski LJ, Kirklin JK, McGiffin D, et al. Multi-organ transplantation: is there a protective effect against acute and chronic rejection? J Heart Lung Transpl. 2005;24:1828–1833.CrossRef
9.
Zurück zum Zitat Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transpl. 2012;12:1504–1510.CrossRef Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transpl. 2012;12:1504–1510.CrossRef
10.
Zurück zum Zitat Wong TW, Gandhi MJ, Daly RC, et al. Liver allograft provides immunoprotection for the cardiac allograft in combined heart–liver transplantation. Am J Transpl. 2016;16:3522–3531.CrossRef Wong TW, Gandhi MJ, Daly RC, et al. Liver allograft provides immunoprotection for the cardiac allograft in combined heart–liver transplantation. Am J Transpl. 2016;16:3522–3531.CrossRef
11.
Zurück zum Zitat Taner T, Heimbach JK, Rosen CB, Nyberg SL, Park WD, Stegall MD. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver–kidney transplantation. Kidney Int. 2016;89:909–917.CrossRef Taner T, Heimbach JK, Rosen CB, Nyberg SL, Park WD, Stegall MD. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver–kidney transplantation. Kidney Int. 2016;89:909–917.CrossRef
12.
Zurück zum Zitat Taner T, Park WD, Stegall MD. Unique molecular changes in kidney allografts after simultaneous liver–kidney compared with solitary kidney transplantation. Kidney Int. 2017;91:1193–1202.CrossRef Taner T, Park WD, Stegall MD. Unique molecular changes in kidney allografts after simultaneous liver–kidney compared with solitary kidney transplantation. Kidney Int. 2017;91:1193–1202.CrossRef
13.
Zurück zum Zitat Lund LH, Khush KK, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transpl. 2017;36:1037–1046.CrossRef Lund LH, Khush KK, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transpl. 2017;36:1037–1046.CrossRef
14.
Zurück zum Zitat Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirty-first official adult heart transplant report–2014; focus theme: retransplantation. J Heart Lung Transpl. 2014;33:996–1008.CrossRef Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirty-first official adult heart transplant report–2014; focus theme: retransplantation. J Heart Lung Transpl. 2014;33:996–1008.CrossRef
15.
Zurück zum Zitat Silberhumer GR, Rahmel A, Karam V, et al. The difficulty in defining extended donor criteria for liver grafts: the eurotransplant experience. Transpl Int. 2013;26:990–998.CrossRef Silberhumer GR, Rahmel A, Karam V, et al. The difficulty in defining extended donor criteria for liver grafts: the eurotransplant experience. Transpl Int. 2013;26:990–998.CrossRef
Metadaten
Titel
Sequential Versus Combined Heart–Liver Transplantation in the USA
verfasst von
Yoshikazu Yamaguchi
Candice Burrier
Catherine Roth
Dmitry Tumin
Eliza W. Beal
Kenneth Washburn
Don Hayes Jr.
Joseph D. Tobias
Publikationsdatum
27.11.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05958-z

Weitere Artikel der Ausgabe 8/2020

Digestive Diseases and Sciences 8/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.